A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13) Authors: Vinita Jagannath, Jayani Pathirana, Carlos Alberto Perez Yepes, Eduardo Lopez-Medina, Juan Andres Navarro, Piotr Korbal, Wanatpreeya Phongsamart, Ayano Inui, Anu Kantele, Jibran E. Atwi, Bruce Tapiero, Derya Alabaz, Fernando Baquero-Artigao, Tiantian Zeng, Danielle Euler, Melanie Papa, Doreen Fernsler, Jun Park, Alejandra Esteves-Jaramillo, Heather L. Platt, the STRIDE-013 Study Group Published: 2026 ABSTRACT ABSTRACTPneumococcal disease (PD) causes significant illness and death, especially in young children, older adults, and individuals with chronic medical conditions. Due to increased risk, children with chronic conditions are often advised to receive additional pneumococcal vaccination beyond the routine primary series. This phase 3 study evaluated the safety and immunogenicity of V116, a 21-valent pneumococcal conjugate vaccine, compared to PPSV23 in children aged 2 to <18 y with certain medical conditions that increase risk of PD who had previously completed a primary pneumococcal vaccination regimen. Individuals with diabetes mellitus, chronic heart, chronic lung, chronic kidney, and/or chronic liver disease were randomized 3:2 to receive a single dose of either V116 (n = 531) or PPSV23 (n = 351). Immunogenicity was assessed at 30 d postvaccination comparing opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) between groups. Safety was evaluated by the proportion of participants with adverse events (AEs). The V116 group met the statistical noninferiority criterion for each of the 12 pneumococcal vaccine serotypes shared between V116 and PPSV23 and additionally met superiority criterion for each of the 9 serotypes unique to V116 based on OPA GMTs. IgG GMCs were consistent with the OPA results. The safety profile was generally comparable between groups. In children and adolescents aged 2 to <18 y with certain medical conditions, V116 is well tolerated and immunogenic. These findings support the use of V116 to broaden pneumococcal serotype coverage in populations at increased risk of pneumococcal disease. Introduction Streptococcus pneumoniae is a major cause of vaccine-preventable illness, known as pneumococcal disease (PD), and contributes substantially to both morbidity and, in severe cases, mortality.1 Among the populations at highest risk, particularly for invasive PD (IPD) such as meningitis, sepsis, and pneumonia, are individuals with pre-existing chronic medical conditions, including diabetes mellitus and chronic heart, lung, liver, and kidney disease.2 Children with these conditions have a much higher risk of IPD and pneumonia compared to children without these risk factors.2–4 As a result, several countries recommend an additional vaccination for children with higher risk; this is after completing, and is complementary to, the primary pneumococcal vaccination regimen to reinforce and broaden disease coverage.5 V116 (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is an adult-specific 21-valent pneumococcal conjugate vaccine (PCV) that is approved in many regions globally (trade name CAPVAXIVE™). Acknowledging the indirect protection afforded by infant vaccination, V116 complements the primary infant vaccination regimen and provides broader disease coverage, including against residual vaccine serotypes still causing disease and additional clinically important serotypes not included in currently licensed vaccines.6–8 V116 contains 8 unique serotypes not contained in any currently licensed pneumococcal vaccine, which cause approximately 40% of IPD in children less than 18 y of age with higher risk for IPD, in the period after PCV13 introduction (2015–2019).9 As such, V116 is a potential candidate for broadening protection in this population. V116 is indicated for the prevention of IPD and pneumonia in adults.7 The global clinical program demonstrated that V116 is well tolerated and immunogenic across a diverse population of adult participants.10–14 This study enrolled children 2 to <18 y of age with certain chronic medical conditions that increase risk of IPD. The safety, tolerability, and immunogenicity of V116 was evaluated in comparison to a current standard of care for this population, which is vaccination with the 23-valent pneumococcal polysaccharide vaccine PPSV23 (MSD). V116 and PPSV23 have 12 vaccine serotypes in common (3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F), while V116 contains 9 serotypes not found in PPSV23 (6A, 15A, de-O-acetylated 15B [this serotype is called 15C from this point forward as it is structurally similar to the 15C polysaccharide and antibodies to 15C were evaluated], 16F, 23A, 23B, 24F, 31, and 35B). Other studies in the V116 clinical program have demonstrated the safety, tolerability, and immunogenicity of V116 in various adult populations, including those with and without pre-existing chronic medical conditions.10–13 Methods Study design This was a randomized, double-blind, active comparator-controlled, parallel-group, multisite study of V116 in children and adolescents aged 2 to <18 y who have completed a primary pneumococcal vaccination regimen and are at increased risk for IPD due to chronic heart disease, chronic lung disease, diabetes mellitus, chronic liver disease, and/or chronic kidney disease. The study was conducted at 92 centers in 13 countries (Canada, Chile, Colombia, Finland, France, Israel, Japan, Poland, Spain, Sweden, Thailand, Türkiye, and the United States) across North America, South America, Europe, and Asia from January 2024 to March 2025 (clinicaltrials.gov NCT06177912 and EUCT 2023-506236-32) and was part of the V116 phase 3 clinical program.10–17 Study setting was mixed, including clinics and research centers in both urban and rural locations. The primary study data were previously presented at a clinical research conference.18 Participant enrollment by country is found in Supp. Table 1.Table 1.Baseline demographics and clinical characteristics. V116(n = 527)PPSV23(n = 347)Total(n = 874) V116(n = 527)PPSV23(n = 347)Total(n = 874)Sex (n (%)) Risk conditions of interest (n (%)) Female219 (41.6)140 (40.3)359 (41.1)1508 (96.4)330 (95.1)838 (95.9)Age in years (n (%)) 2+19 (3.6)17 (4.9)36 (4.1) ≥2 to <6165 (31.3)107 (30.8)272 (31.1)Prior PCV primary regimen ≥6 to <18361 (68.5)240 (69.2)601 (68.8)3 + 1 regimen201 (38.1)140 (40.3)341 (39.0) ≥18a1 (0.2)0 (0.0)1 (0.1)2 + 1 regimen303 (57.5)189 (54.5)492 (56.3) Median (range)8.0 (2 to 18)7.0 (2 to 17)8.0 (2 to 18)Otherb23 (4.4)18 (5.2)41 (4.7)Race (n (%)) Prior pneumococcal vaccination (n (%)) American Indian or Alaska Native48 (9.1)43 (12.4)91 (10.4)Prior PCV13302 (57.3)195 (56.2)497 (56.9) Asian47 (8.9)37 (10.7)84 (9.6)Prior PCV10176 (33.4)111 (32.0)287 (32.8) Black or African American31 (5.9)19 (5.5)50 (5.7)Prior PCV731 (5.9)24 (6.9)55 (6.3) White321 (60.9)200 (57.6)521 (59.6)Prior PCV13 and one PPSV23 dose5 (0.9)4 (1.2)9 (1.0) Multiple80 (15.2)48 (13.8)128 (14.6)Prior PCV10 and one PPSV23 dose4 (0.8)2 (0.6)6 (0.7)Ethnicity (n (%)) Prior PCV7 and one PPSV23 dose2 (0.4)2 (0.6)4 (0.5) Hispanic or Latino231 (43.8)157 (45.2)388 (44.4)Otherc6 (1.1)9 (2.6)15 (1.7)aIncludes a participant who was 18 y and 3 months of age at time of enrollment.bIncludes any regimen other than 3 + 1 or 2 + 1, and one participant with missing data.cIncludes any combinations of prior pneumococcal vaccines, and one participant with missing data.PCV7 = pneumococcal 7-valent conjugate vaccine; PCV10 = pneumococcal 10-valent conjugate vaccine; PCV13 = pneumococcal 13-valent conjugate vaccine; PPSV23 = pneumococcal vaccine, polyvalent (23-valent). Table 1.Baseline demographics and clinical characteristics. V116(n = 527)PPSV23(n = 347)Total(n = 874) V116(n = 527)PPSV23(n = 347)Total(n = 874)Sex (n (%)) Risk conditions of interest (n (%)) Female219 (41.6)140 (40.3)359 (41.1)1508 (96.4)330 (95.1)838 (95.9)Age in years (n (%)) 2+19 (3.6)17 (4.9)36 (4.1) ≥2 to <6165 (31.3)107 (30.8)272 (31.1)Prior PCV primary regimen ≥6 to <18361 (68.5)240 (69.2)601 (68.8)3 + 1 regimen201 (38.1)140 (40.3)341 (39.0) ≥18a1 (0.2)0 (0.0)1 (0.1)2 + 1 regimen303 (57.5)189 (54.5)492 (56.3) Median (range)8.0 (2 to 18)7.0 (2 to 17)8.0 (2 to 18)Otherb23 (4.4)18 (5.2)41 (4.7)Race (n (%)) Prior pneumococcal vaccination (n (%)) American Indian or Alaska Native48 (9.1)43 (12.4)91 (10.4)Prior PCV13302 (57.3)195 (56.2)497 (56.9) Asian47 (8.9)37 (10.7)84 (9.6)Prior PCV10176 (33.4)111 (32.0)287 (32.8) Black or African American31 (5.9)19 (5.5)50 (5.7)Prior PCV731 (5.9)24 (6.9)55 (6.3) White321 (60.9)200 (57.6)521 (59.6)Prior PCV13 and one PPSV23 dose5 (0.9)4 (1.2)9 (1.0) Multiple80 (15.2)48 (13.8)128 (14.6)Prior PCV10 and one PPSV23 dose4 (0.8)2 (0.6)6 (0.7)Ethnicity (n (%)) Prior PCV7 and one PPSV23 dose2 (0.4)2 (0.6)4 (0.5) Hispanic or Latino231 (43.8)157 (45.2)388 (44.4)Otherc6 (1.1)9 (2.6)15 (1.7)aIncludes a participant who was 18 y and 3 months of age at time of enrollment.bIncludes any regimen other than 3 + 1 or 2 + 1, and one participant with missing data.cIncludes any combinations of prior pneumococcal vaccines, and one participant with missing data.PCV7 = pneumococcal 7-valent conjugate vaccine; PCV10 = pneumococcal 10-valent conjugate vaccine; PCV13 = pneumococcal 13-valent conjugate vaccine; PPSV23 = pneumococcal vaccine, polyvalent (23-valent). Baseline demographics and clinical characteristics. aIncludes a participant who was 18 y and 3 months of age at time of enrollment. bIncludes any regimen other than 3 + 1 or 2 + 1, and one participant with missing data. cIncludes any combinations of prior pneumococcal vaccines, and one participant with missing data. PCV7 = pneumococcal 7-valent conjugate vaccine; PCV10 = pneumococcal 10-valent conjugate vaccine; PCV13 = pneumococcal 13-valent conjugate vaccine; PPSV23 = pneumococcal vaccine, polyvalent (23-valent). The study design planned for enrollment of 820 participants, randomized 3:2 to receive a single vaccination with either V116 (n = 492) or PPSV23 (n = 328), respectively. Intervention randomization occurred centrally using electronic intervention randomization system (IRT or Interactive Response Technology). Participants were assigned randomly in a 3:2 ratio to receive either V116 or PPSV23, respectively. Randomization was stratified by number of at-risk conditions, prior pneumococcal vaccination, and age. Safety and immunogenicity by stratification factors are the subject of a separate publication. A double-blinding technique was used. Study vaccines were prepared and administered by unblinded site personnel who were not involved in any subsequent participant assessments or procedures. The participant, participant’s legally acceptable representative, the investigator, and Sponsor personnel or delegate(s) who were involved in the study intervention administration or clinical evaluation of the participants were unaware of the intervention assignments. Safety oversight was provided by an external independent data monitoring committee that conducted periodic reviews. The study was conducted in accordance with the principles of Good Clinical Practice and received approval from the appropriate institutional review boards/ethics committees. A scientific advisory committee comprised of external and MSD scientists contributed to the development of the protocols and statistical analysis plan. Participants Eligible participants were children and adolescents aged 2 to <18 y with a documented diagnosis of: diabetes mellitus receiving treatment with antidiabetic medication, chronic compensated liver disease, chronic lung disease, including but not limited to asthma (a diagnosis of asthma requires being on active medical therapy), chronic heart disease (heart failure, congenital heart disease, cardiomyopathy, and/or valvular heart disease), and/or chronic kidney disease with chronic renal insufficiency/impairment. Risk conditions were stably managed for at least 3 months prior to study enrollment. Participants had completed a primary PCV regimen with PCV7, PCV10, or PCV13 using a 2 + 1 or 3 + 1 regimen at least 8 weeks prior to enrollment and were either PPSV23 naïve or had received a single dose of PPSV23 ≥5 y prior to study enrollment. Written informed consent was obtained from each participant by their legally acceptable representative prior to any study procedure. Key exclusion criteria were as follows: had a curative procedure for chronic heart disease that does not require further management per local guidelines; active hepatitis within 3 months before study vaccination; history of diabetic ketoacidosis or 2 or more episodes of severe, symptomatic hypoglycemia within 3 months before study vaccination; severely reduced kidney function, dialysis, autoimmune kidney disease, nephrotic syndrome, or any acute/reversible cause of kidney disease; severe pulmonary hypertension or Eisenmenger syndrome; IPD within 3 y of study vaccination; known hypersensitivity to any component of PPSV23 or V116; had a known or suspected impairment of immunological function, or receipt of immunosuppressive therapy. Vaccines and administration V116 (MSD) is a 21-valent PCV containing 4 µg of each of the following pneumococcal capsular polysaccharides (PnPs): 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B, with each serotype conjugated to CRM197. PPSV23 (MSD) contains 25 µg of each of PnPs 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9 V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. While the PPSV23 label states it contains serotype 20, advances in serotyping methods have led to further characterization of this serotype to be 20A.19 V116 also contains serotype 20A, making this a common serotype between the vaccines. Study vaccines were supplied as prefilled syringes and stored at 2–8°C. A 0.5-mL intramuscular dose of each study vaccine was administered, and participants were observed for at least 30 minutes postvaccination. Immunogenicity assessments To assess immunogenicity outcomes, blood was collected prior to and 30 d after study vaccination. Serotype-specific anti-PnPs antibodies were measured using a multiplexed electrochemiluminescence assay. Functional antibodies were measured using a serotype-specific microcolony multiplex opsonophagocytic killing assay. Both assays were developed by MSD.20,21 The primary immunogenicity outcome was to compare the PnPs-specific opsonophagocytic (OPA) geometric mean titers (GMTs) at 30 d postvaccination with V116 or PPSV23. To assess the hypothesis of noninferiority of V116 to PPSV23 for the 12 serotypes both vaccines have in common, the statistical criterion for noninferiority required the lower bound of the 2-sided 95% confidence interval (CI) of the OPA GMT ratio (V116/PPSV23) to be >0.5. To assess the hypothesis of superiority of V116 to PPSV23 for the 9 serotypes unique to V116, the statistical criterion for superiority required the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) to be >2.0. Secondary immunogenicity outcomes included evaluation of PnPs-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 d postvaccination, as well as geometric mean fold rises (GMFRs) and the proportions of participants with a ≥4-fold rise in serotype-specific OPA and IgG responses from baseline to 30 d postvaccination. For the primary outcome, estimation of the ratios and 95% CIs were calculated using the constrained longitudinal data analysis method proposed by Liang and Zeger.22 For other immunogenicity outcomes, descriptive statistics with point estimates and 95% CIs were provided. Immunogenicity analyses were conducted on the “per protocol” population, which consisted of all randomized participants without protocol deviations that may substantially affect results of the immunogenicity endpoints. Safety assessments The primary safety outcome was to evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs). Solicited injection-site (pain, swelling, erythema) and systemic (fatigue, headache, malaise, irritability, somnolence, myalgia, pyrexia, arthralgia, urticaria) AEs were recorded by legally acceptable representatives using an electronic vaccination report card through day 5 following study vaccination. All other AEs were reported for 30 d after study vaccination, and serious AEs (SAEs) and deaths were reported throughout the study. All recorded events were reviewed by study investigators to determine if they met protocol-defined AE criteria and to assess seriousness, intensity, and causality to the study vaccine. Point estimates and 95% CIs were provided for the primary safety outcome. Safety analyses were conducted on the “all participants as treated” population, which consisted of all randomized participants who received a study vaccination. Determination of study sample size For the primary immunogenicity outcome, the planned enrollment of 820 participants afforded >90% power to declare noninferiority of V116 to PPSV23 for the 12 common serotypes and superiority of V116 to PPSV23 for the 9 unique serotypes at an overall 1-sided 2.5% alpha-level (assuming 90% evaluability). For the 12 common serotypes, underlying assumptions from prior study experience were that OPA GMT ratios (V116/PPSV23) would range from 0.84 to 1.74 and standard deviations would range from 0.93 to 1.43 (V116) and 0.96 to 1.43 (PPSV23). For the 9 unique serotypes, OPA GMT ratios would range from 2.90 to 23.72 and standard deviations would range from 1.03 to 1.52 (V116) and 1.05 and 2.54 (PPSV23). For safety, there was an 80% probability of observing at least 1 SAE among 492 participants in the V116 group if the true incidence rate is 0.33%, and a 50% probability of observing at least 1 SAE in the V116 group if the true incidence rate is 0.14%. Analysis software All analyses were performed using SAS software, version 9.4, of the SAS System for Unix (copyright 2012 SAS Institute, Inc). Results Participant characteristics A total of 882 participants were randomized into V116 (n = 531) and PPSV23 (n = 351) groups. In both groups, 98.3% of participants completed the study, with parent-initiated withdrawal as the most common reason for discontinuation (Figure 1). Baseline demographics were balanced between groups for sex, age, race, and ethnicity. The majority of participants were male, White, non-Hispanic, while Hispanic or Latino, Asian, Black or African American, and American Indian or Alaskan Native individuals were represented among the participants (Table 1). The majority of participants were aged 6 to <18 y and had a single risk condition of interest upon enrollment, with the most common being chronic lung disease (Table 1 and Supp. Table 2). The majority of participants previously received a 2 + 1 primary vaccination regimen, with PCV13 being the most common prior pneumococcal vaccine received (Table 1). Figure 1.Participant disposition.The flowchart details the disposition of 882 participants in a study. Part icipants were divided into two groups: V116 Group with 531 participants and PPSV23 Group with 351 participants. In the V116 Group, 3 participants (0.6 percent) were excluded due to randomization mistakes and parent withdrawal. This left 528 participants for vaccination with V116. Six participants (1.1 percent) discontinued, with reasons including loss to follow-up, parent withdrawal and other reasons. The trial was completed by 522 participants (98.3 percent). In the PPSV23 Group, 3 participants (0.9 percent) were excluded for similar reasons, leaving 348 for vaccination. Three participants (0.9 percent) discontinued due to parent withdrawal and death. The trial was completed by 345 participants (98.3 percent).Participant disposition for the V116-013 study.Table 2.Safety summary. V116PPSV23 n = 527n = 347V116-PPSV23% difference (95% CI)≥1 AE; n (%)426 (80.8)264 (76.1)4.8 (−0.8, 10.5) Injection-site AEs382 (72.5)202 (58.2) Systemic AEs313 (59.4)204 (58.8) Vaccine-related AEs*; n (%)404 (76.7)234 (67.4)9.2 (3.2, 15.4) Injection-site AEs382 (72.5)202 (58.2) Systemic AEs231 (43.8)141 (40.6) SAEs; n (%)29 (5.5)25 (7.2)−1.7 (−5.3, 1.5) Serious vaccine-related AEs*1 (0.2)2 (0.6)−0.4 (−1.9, 0.6)Deaths; n (%)0 (0.0)2 (0.6)−0.6 (−2.1, 0.2)*Determined by the investigator to be related to the vaccine. Participant disposition. Table 2.Safety summary. V116PPSV23 n = 527n = 347V116-PPSV23% difference (95% CI)≥1 AE; n (%)426 (80.8)264 (76.1)4.8 (−0.8, 10.5) Injection-site AEs382 (72.5)202 (58.2) Systemic AEs313 (59.4)204 (58.8) Vaccine-related AEs*; n (%)404 (76.7)234 (67.4)9.2 (3.2, 15.4) Injection-site AEs382 (72.5)202 (58.2) Systemic AEs231 (43.8)141 (40.6) SAEs; n (%)29 (5.5)25 (7.2)−1.7 (−5.3, 1.5) Serious vaccine-related AEs*1 (0.2)2 (0.6)−0.4 (−1.9, 0.6)Deaths; n (%)0 (0.0)2 (0.6)−0.6 (−2.1, 0.2)*Determined by the investigator to be related to the vaccine. Safety summary. *Determined by the investigator to be related to the vaccine. Immunogenicity Immunogenicity of the study vaccines was assessed by measuring PnPs-specific antibodies at 30 d following vaccination. For OPA GMTs, V116 met the pre-specified noninferiority criterion for each of the 12 serotypes in common between V116 and PPSV23 (Figure 2(A)). For the 9 serotypes not found in PPSV23, V116 met the pre-specified superiority criterion for each serotype (Figure 2(B)). Antibody levels by IgG GMCs at 30 d following vaccination were generally comparable between groups for the 12 serotypes common to both study vaccines, and generally higher for the 9 serotypes unique to V116 (Figure 3). OPA and IgG data were overall consistent across vaccine serotypes. Taking baseline antibody levels into account, the proportion of participants with a ≥4-fold rise in serotype-specific OPA and IgG responses from baseline to 30 d following vaccination were generally comparable between groups for common serotypes, and higher for serotypes unique to V116 (Figure 4 and Supp. Tables 3, 4). Within serogroups 6 and 15, V116 induced cross-reactive immune responses to non-vaccine serotypes 6C (from vaccine serotype 6A) and 15B (from vaccine serotype 15C) (Supp. Table 5). Figure 2.Serotype-specific OPA GMT ratios with 95% confidence intervals for common serotypes (A) and serotypes unique to V116 (B) 30 d following vaccination. OPA GMTs and n for each serotype are next to the figure.The image A showing a forest plot of common serotypes. The y-axis is labeled Common serotypes, listing 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, 33F. The x-axis is labeled GMT ratio log subscript 2 scale (V116 slash PPSV23), with ticks at 0.5, 1, 2, 4, 8. A vertical dashed line at 0.5 is labeled noninferiority margin 0.5. Point estimates with 95 percent confidence intervals and the table values are: 3, 1.02 (0.89, 1.17); 7F, 1.45 (1.24, 1.70); 8, 1.37 (1.20, 1.56); 9N, 1.91 (1.64, 2.23); 10A, 2.56 (2.18, 3.00); 11A, 3.32 (2.80, 3.95); 12F, 3.06 (2.62, 3.58); 17F, 3.55 (3.02, 4.17); 19A, 0.92 (0.78, 1.08); 20A, 2.54 (2.13, 3.02); 22F, 2.59 (2.21, 3.04); 33F, 1.80 (1.54, 2.11). Table columns show V116 n and GMT, PPSV23 n and GMT: 3, 488 and 526.6; 314 and 517.0. 7F, 486 and 20618.1; 315 and 14207.2. 8, 485 and 12294.5; 313 and 8966.9. 9N, 485 and 35556.8; 315 and 18587.8. 10A, 485 and 13719.7; 311 and 5363.8. 11A, 486 and 10396.3; 312 and 3129.8. 12F, 486 and 14752.0; 314 and 4820.1. 17F, 481 and 40011.8; 312 and 11267.4. 19A, 486 and 9009.8; 314 and 9797.6. 20A, 480 and 37532.2; 311 and 14787.0. 22F, 487 and 20162.7; 313 and 7770.3. 33F, 488 and 73201.8; 314 and 40609.0. The image B showing a forest plot of unique serotypes. The y-axis is labeled Unique serotypes, listing 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, 35B. The x-axis is labeled GMT ratio log subscript 2 scale (V116 slash PPSV23), with ticks at 2, 4, 8, 16, 32. A vertical dashed line at 2.0 is labeled superiority margin 2.0. Point estimates with 95 percent confidence intervals and the table values are: 6A, 2.99 (2.46, 3.64); 15A, 13.04 (11.13, 15.27); 15C, 7.85 (6.29, 9.81); 16F, 5.79 (5.01, 6.69); 23A, 5.86 (4.88, 7.03); 23B, 16.16 (12.03, 21.72); 24F, 4.01 (3.40, 4.72); 31, 18.01 (15.09, 21.50); 35B, 5.13 (4.45, 5.93). Table columns show V116 n and GMT, PPSV23 n and GMT: 6A, 480 and 16910.9; 311 and 5653.8. 15A, 485 and 69527.8; 315 and 5332.2. 15C, 480 and 34539.1; 308 and 4398.4. 16F, 485 and 31544.9; 313 and 5449.7. 23A, 474 and 28591.7; 296 and 4882.0. 23B, 485 and 5988.2; 312 and 370.5. 24F, 478 and 11102.2; 297 and 2771.8. 31, 484 and 46163.7; 311 and 2563.0. 35B, 482 and 40102.8; 311 and 7812.5.Forest plots displaying the OPA GMT ratios for serotypes common to V116 and PPSV23 and serotypes unique to V116. Figure 3.Serotype-specific IgG GMCs with 95% confidence intervals 30 d following vaccination. Data for V116 (green bars) and PPSV23 (red bars) groups are shown.A grouped bar graph showing IgG geometric mean concentration by serotype for V116 and PPSV23. Legend: V116; PPSV23. Y axis label: IgG GMC left parenthesis log subscript 10 right parenthesis, unit not shown; tick labels 0.1, 1, 10. X axis label: none; categories: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, 33F, 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, 35B. Brackets under x axis: Common serotypes for 3 through 33F; V116 unique serotypes for 6A through 35B. Each category has two vertical bars with error bars. Approximate bar heights: 3 V116 about 1.5, PPSV23 about 1.8; 7F about 7 and 7; 8 about 12 and 15; 9N about 7 and 9; 10A about 9 and 5; 11A about 7 and 5; 12F about 1.7 and 1.3; 17F about 14 and 6; 19A about 13 and 15; 20A about 9 and 6; 22F about 13 and 10; 33F about 7 and 9; 6A about 11 and 6; 15A about 11 and 1.2; 15C about 12 and 2.5; 16F about 2.5 and 0.2; 23A about 7 and 1.1; 23B about 6.5 and 1.3; 24F about 2.5 and 0.25; 31 about 5 and 0.3; 35B about 9 and 0.9.Bar graph displaying IgG GMCs for serotypes common to V116 and PPSV23 and serotypes unique to V116. Figure 4.Proportion of participants (%) with a ≥4-fold rise in serotype-specific OPA responses (with 95% confidence intervals) from baseline to 30 d following vaccination. Data for V116 (green bars) and PPSV23 (red bars) groups are shown.A grouped bar graph with error bars comparing V116 and PPSV23. Y axis label percent greater than or equal to 4 fold rise in OPA titers, unit percent, range 0 to 100. X axis lists serotypes: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, 33F, 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, 35B. Brackets label Common serotypes for 3 through 33F and V116 unique serotypes for 6A through 35B. Legend entries: V116 and PPSV23. Visible bar heights, approximate percent: Serotype 3 V116 about 65, PPSV23 about 68. 7F V116 about 85, PPSV23 about 80. 8 V116 about 92, PPSV23 about 90. 9N V116 about 84, PPSV23 about 72. 10A V116 about 75, PPSV23 about 48. 11A V116 about 78, PPSV23 about 46. 12F V116 about 97, PPSV23 about 96. 17F V116 about 93, PPSV23 about 75. 19A V116 about 58, PPSV23 about 65. 20A V116 about 78, PPSV23 about 48. 22F V116 about 85, PPSV23 about 66. 33F V116 about 90, PPSV23 about 75. 6A V116 about 78, PPSV23 about 55. 15A V116 about 92, PPSV23 about 22. 15C V116 about 92, PPSV23 about 70. 16F V116 about 68, PPSV23 about 12. 23A V116 about 76, PPSV23 about 28. 23B V116 about 80, PPSV23 about 42. 24F V116 about 48, PPSV23 about 8. 31 V116 about 92, PPSV23 about 12. 35B V116 about 60, PPSV23 about 8.Bar graph displaying the percent of participants with at least a 4-fold rise in OPA titers after vaccination, for serotypes common to V116 and PPSV23 and serotypes unique to V116. Serotype-specific OPA GMT ratios with 95% confidence intervals for common serotypes (A) and serotypes unique to V116 (B) 30 d following vaccination. OPA GMTs and n for each serotype are next to the figure. Serotype-specific IgG GMCs with 95% confidence intervals 30 d following vaccination. Data for V116 (green bars) and PPSV23 (red bars) groups are shown. Proportion of participants (%) with a ≥4-fold rise in serotype-specific OPA responses (with 95% confidence intervals) from baseline to 30 d following vaccination. Data for V116 (green bars) and PPSV23 (red bars) groups are shown. Safety In both groups, the majority of participants experienced one or more AEs following vaccination (80.8% in V116 group, 76.1% in PPSV23 group). The proportion of participants with injection-site AEs was numerically higher in the V116 group (72.5% in V116 group and 58.2% in PPSV23 group), while systemic AEs and SAEs were generally comparable between groups (Table 2 and Supp. Table 6). There was a single SAE of syncope in the V116 group that was considered by the investigator to be related to the vaccine and was moderate in intensity. The proportions of participants with individual solicited AEs was comparable for all except injection-site pain and erythema, which were numerically higher in the V116 group (Figure 5). Most solicited AEs in both groups were of mild to moderate intensity and of short (≤3 d) duration (Figure 5 and Supp. Table 7). There were two deaths (septic shock and cardiopulmonary failure) during the study, neither of which was considered related to a study vaccine by the investigator. Figure 5.Solicited AEs by severity. The proportions of participants with individual solicited AEs following study vaccination are shown by maximum intensity.A stacked bar graph titled Injection site and Systemic. Legend: Mild, Moderate, Severe. Y-axis label Proportion of participants left parenthesis percent right parenthesis, range 0 to 100. X-axis categories: Pain, Erythema, Swelling, Fatigue, Headache, Malaise, Irritability, Somnolence, Myalgia, Pyrexia, Arthralgia, Urticaria; each category has two bars labeled V116 and PPSV23. Values shown above bars: Pain V116 67.7, PPSV23 54.5. Erythema V116 24.3, PPSV23 16.4. Swelling V116 18.8, PPSV23 18.2. Fatigue V116 20.1, PPSV23 21.0. Headache V116 17.1, PPSV23 15.3. Malaise V116 13.3, PPSV23 9.2. Irritability V116 11.6, PPSV23 11.0. Somnolence V116 9.5, PPSV23 9.2. Myalgia V116 6.3, PPSV23 5.2. Pyrexia V116 4.6, PPSV23 5.8. Arthralgia V116 4.4, PPSV23 5.5. Urticaria V116 2.7, PPSV23 1.7.A stacked bar graph showing solicited injection-site and systemic adverse events by severity following V116 or PPSV23. Solicited AEs by severity. The proportions of participants with individual solicited AEs following study vaccination are shown by maximum intensity. Discussion Preventing IPD in children and adolescents with underlying medical conditions is a high public health priority. For other licensed PCVs, evidence suggests lower vaccine effectiveness in these populations compared to children without risk conditions following completion of the infant/toddler series.23,24 This may be due to increased severity of disease in the higher risk population, the non-vaccine serotypes causing disease, or other factors. Accordingly, several health authorities recommend supplemental or differentiated pneumococcal vaccination for these children to bolster vaccine-induced protection and broaden serotype coverage. This study evaluated the safety and immunogenicity of V116 compared to PPSV23 in this population. Current pneumococcal vaccination recommendations for at-risk children vary, with PCV15, PCV20, and/or PPSV23 being the most recommended supplemental vaccination given to children who have already completed the primary PCV series.25,26 PPSV23 was used as comparator in this study for two reasons. First, it is the most recommended supplemental vaccination for this population globally and has the broadest serotype coverage available. Second, PPSV23 shares the most serotypes with V116 (12 serotypes), which makes it useful as a comparator when evaluating immunogenicity in this population. V116 was designed to complement the primary pneumococcal vaccination series by providing protection against prevalent serotypes not commonly included in infant-recommended vaccines that are more prevalent in adults. Therefore, V116 may provide broader, more differentiated vaccine-mediated coverage against disease-causing serotypes when used as a supplement in addition to currently recommended primary PCV regimens. Other studies in the V116 clinical program evaluated V116 along with PCV15 or PCV20 as comparator.12–14 Immunogenicity comparisons between V116 and PPSV23 were based on pre-specified hypotheses with statistical criteria for shared and unique serotypes. V116 met the pre-defined criteria for all 21 serotypes, as measured by OPA GMTs. For the 12 shared serotypes, V116 achieved noninferiority and additionally elicited numerically higher OPA GMTs than PPSV23 for most serotypes. As expected, V116 was superior for all unique serotypes. PPSV23 contains serotypes 6B and 15B, which exhibit partial cross-reactivity within their respective serogroups (serogroups 6 and 15).27,28 While antibody levels were evident in this study by IgG GMCs for serotypes 6A, 15A, and 15C after vaccination with PPSV23, V116 achieved higher IgG GMCs and was also superior to PPSV23 for OPA GMTs. Moreover, both Li, et.al. and the pivotal phase 3 V116 trial demonstrated cross-reactive responses to non-vaccine serotypes 15B and 6C by both OPA GMTs and IgG GMCs.12,28 While cross-reactive antibodies against non-vaccine serotypes 6C and 15B were demonstrated, it is unclear whether this translates into clinical protection. The overall safety profile was generally comparable between the study groups. V116 was well tolerated, and most AEs were of mild or moderate intensity and of short duration, and SAEs were rare. There was an increase in injection-site AEs, particularly injection-site pain, in the V116 group. However, the clinical relevance of the observed difference in injection‑site pain remains uncertain; events were mostly mild to moderate, and of short duration. The absence of severe or persistent events suggests limited impact on overall tolerability. Similar patterns of increased local reactions have been reported in trials comparing conjugate and polysaccharide vaccines, including meningococcal, typhoid, and PCV vaccines.29–31 A strength of this study was the inclusion of a large, geographically and ethnically diverse participant population of children with chronic conditions associated with an increased risk of IPD. The represented conditions account for a substantial portion of children at increased IPD risk and may be generalizable to other chronic conditions not included in this study. The use of pre-specified hypotheses allowed for statistical comparison between treatment groups. Study limitations include lack of long-term immunogenicity or effectiveness data after V116 administration. Since no defined correlates of protection are established for assessing the serotype-specific immunogenicity of PCVs in older children and adults, OPA data are presented. In addition, immunosuppressed individuals were excluded, so it is unknown whether vaccine performance would be similar in this high-risk population. Nonetheless, prior adult studies in high-risk groups have demonstrated V116 to be well tolerated and immunogenic.14,16 While study participants were from 13 countries across 4 continents, not all geographic regions were represented in the study. In conclusion, V116 is well tolerated and immunogenic in children and adolescents aged 2 to <18 y with chronic medical conditions that increase the risk of IPD. The serotypes contained in V116 may offer broader protection for population at increased risk of pneumococcal disease and help address an unmet need in prevention of PD. Supplementary Material V116_013 Supplementary data HVI.docx